London Holds Exhibition to Highlight Scythian Culture

Scythians with horses under a tree. Gold belt plaque. Siberia, 4th–3rd century BC. (The State Hermitage Museum, St Petersburg, 2017)
Scythians with horses under a tree. Gold belt plaque. Siberia, 4th–3rd century BC. (The State Hermitage Museum, St Petersburg, 2017)
TT

London Holds Exhibition to Highlight Scythian Culture

Scythians with horses under a tree. Gold belt plaque. Siberia, 4th–3rd century BC. (The State Hermitage Museum, St Petersburg, 2017)
Scythians with horses under a tree. Gold belt plaque. Siberia, 4th–3rd century BC. (The State Hermitage Museum, St Petersburg, 2017)

The Scythian people, predecessors of the Mongols, ruled a massive area of the Eurasian steppe located between Northern China and the Black Sea, between the ninth and the second century B.C. Little has been known about their culture, until now.

The “Scythians: Warriors of Ancient Siberia” exhibition was launched at the British Museum in London to change the people’s perception of this ancient culture.

Back then, people feared the Scythians, calling them “warriors on horseback”. They used to drink milk from the skulls of their enemies, tattoo themselves with charcoal and consume cannabis.

The Scythians, who spoke Persian, had no written language, so information about them comes from ancient Greeks, Assyrians and Persians.

The exhibition’s website reads: "For centuries, all traces of their culture was missing, and buried under the ice.”

The exhibition, which runs until January 14, wonders whether the civilization is the inspiration behind the famous "Game of Thrones" book and television series.

Most of the 200 pieces featured in the exhibition come from southern Siberia. Many of them are borrowed from the Hermitage Museum in St. Petersburg and are being exhibited outside of Russia for the first time.

The artifacts are are well preserved because they have been buried under ice in the burial hills and tombs of the Altai Mountains in Central Asia.

The exhibit includes pieces discovered at archaeological excavations during the rule of Russia’s Peter the Great in the early 18th century. They include the head of a chief from Scythian tribal, displaying his tattooed skin and glittering gold necklaces. Other pieces include embellished gold for men and women, pendants, leather shoes, and some well-preserved pieces of cheese.

According to the German News Agency (dpa), the exhibit also features engraved stone and massive sarcophagi.

The Scythians, predecessors of the Huns and Mongols, revered horses and relied on them in their wars. Horses, adorned with heavy embellishments, were often buried with their owners to accompany them in their afterlife.



Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”